FDA APPROVES NEW ORAL THERAPY FOR RELAPSING MS

The U.S. Food and Drug Administration (FDA) has approved Tecfidera ™. This makes the third oral therapy approved for relapsing MS and tenth disease modifying treatment available in the U.S.

In less than two decades, MS has moved from an untreatable disease to one where there are now 10 FDA approved disease modifying therapies for relapsing MS, the most common form of the disease, and a significant number of other exciting therapies in late stage development or already before the FDA for review.

This approval is a great step forward for the MS community! It is also a major advancement to share with your public officials about why continuing to fund MS research and the FDA is so important. To read more, please visit  http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7539